The Weight of HLA-DPA1 rs3077 Single Nucleotide Polymorphism in Prostate Cancer, a Multicenter Study

Table 1

Patients’ demographics.

	Prostate cancer (n = 40)	Control (n = 40)	t or U
Age (years)	59.9 ± 9.2	56.3 ± 10.3	t = 1.635	0.106
BMI	22.68 ± 6.17	24.68 ± 4.17		0.105
Smoking	13 (8%)	8 (3.2%)		0.12
Medical comorbidity
Diabetes mellitus	1 (2.5%)	0 (0%)
Hypertension	3 (7.5%)	4 (10.0%)		0.107
Hepatic fibrosis	1 (2.5%)	0 (0%)
Nephropathy	2 (5.0%)	3 (7.5%)
S. urea (mg/dl)	26.6 ± 5.7	14.3 ± 2.8	t = 12.123	<0.001
S. creatinine (mg/dl)	1.22 ± 0.23	0.85 ± 0.04	t = 9.598	<0.001
Total serum PSA (ng/ml)	1.8 ± 0.97	1 ± 0.83	U = 370.5	<0.001
Free serum PSA (ng/ml)	0.51 ± 0.32	0.6 ± 0.73	U = 670.0	0.227
PSA ratio (free-to-total PSA) (%)
Mean ± SD	37 ± 6.2	18.5 ± 3.6	U = 0.0	<0.001
Median (min–max)	35.6 (27.3–56.59)	17.32 (10.65–25)

t, student's t-test; U, Mann–Whitney test; , value for comparing between the studied groups. Statistically significant at .